255 related articles for article (PubMed ID: 8832602)
1. Comparison of plasma erythropoietin concentrations and iron status in hemodialyzed patients not requiring and requiring rHuEpo therapy.
Majdan M; Ksiazek A; Kozioł M; Spasiewicz D; Swatowski A; Solski J
Nephron; 1996; 73(3):425-9. PubMed ID: 8832602
[TBL] [Abstract][Full Text] [Related]
2. Changes of endogenous erythropoietin level and iron status during a 30-month hemodialysis treatment of a group of patients.
Majdan M; Ksiazek A; Bednarek-Skublewska A; Spasiewicz D
Int Urol Nephrol; 2001; 33(3):541-6. PubMed ID: 12230292
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of selected parameters of dialysis quality in hemodialysis patients not requiring and requiring treatment with erythropoietin].
Majdan M; Ksiazek A; Swatowski A
Pol Arch Med Wewn; 1995 Jan; 93(1):58-62. PubMed ID: 7479219
[TBL] [Abstract][Full Text] [Related]
4. Anemia and carnitine supplementation in hemodialyzed patients.
Kletzmayr J; Mayer G; Legenstein E; Heinz-Peer G; Leitha T; Hörl WH; Kovarik J
Kidney Int Suppl; 1999 Mar; 69():S93-106. PubMed ID: 10084293
[TBL] [Abstract][Full Text] [Related]
5. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
Tarng DC; Huang TP; Chen TW
Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of the ability to control anemia in patients on hemodialysis and peritoneal dialysis considering iron reserves and plasma erythropoietin].
Majdan M; Ksiazek A; Spasiewicz D
Pol Arch Med Wewn; 1996 Apr; 95(4):307-12. PubMed ID: 8755836
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload.
Tarng DC; Huang TP; Chen TW; Yang WC
Kidney Int Suppl; 1999 Mar; 69():S107-18. PubMed ID: 10084294
[TBL] [Abstract][Full Text] [Related]
8. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
Lin CL; Hsu PY; Yang HY; Huang CC
Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
[TBL] [Abstract][Full Text] [Related]
9. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
[TBL] [Abstract][Full Text] [Related]
10. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
11. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.
Ahluwalia N; Skikne BS; Savin V; Chonko A
Am J Kidney Dis; 1997 Oct; 30(4):532-41. PubMed ID: 9328369
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
[TBL] [Abstract][Full Text] [Related]
13. Relative contributions of body iron status and uremia severity to anemia in patients with advanced chronic renal failure.
Ifudu O; Dawood M; Friedman EA
Nephron; 1997; 77(3):315-8. PubMed ID: 9375826
[TBL] [Abstract][Full Text] [Related]
14. [Anemia in peritoneal dialysis patients].
Lausević M; Nesić V; Jovanović N; Stojimirović B
Srp Arh Celok Lek; 2006; 134(3-4):133-7. PubMed ID: 16915754
[TBL] [Abstract][Full Text] [Related]
15. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
16. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.
Jungers P; Choukroun G; Oualim Z; Robino C; Nguyen AT; Man NK
Nephrol Dial Transplant; 2001 Feb; 16(2):307-12. PubMed ID: 11158405
[TBL] [Abstract][Full Text] [Related]
17. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.
Fishbane S; Berns JS
Kidney Int; 2005 Sep; 68(3):1337-43. PubMed ID: 16105069
[TBL] [Abstract][Full Text] [Related]
18. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
20. Effect of rHuEpo therapy in dialysis patients on endogenous erythropoietin synthesis after renal transplantation.
Fernández Lucas M; Marcén R; Villafruela J; Teruel JL; Tato A; Rivera M; Ortuño J
Nephron; 1996; 73(1):54-7. PubMed ID: 8742957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
